Axsome Therapeutics
AXSM
174 hedge funds and large institutions have $827M invested in Axsome Therapeutics in 2022 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 67 increasing their positions, 46 reducing their positions, and 25 closing their positions.
46% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 46
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
5.8% more ownership
Funds ownership: 49.69% → 55.5% (+5.8%)
8% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 25
4% more capital invested
Capital invested by funds: $791M → $827M (+$35.6M)
0% more funds holding
Funds holding: 174 → 174 (0)
4% less call options, than puts
Call options by funds: $106M | Put options by funds: $110M
Top Buyers
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$43M |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
+$11M |
| 3 |
Millennium Management
New York
|
+$10.4M |
| 4 |
Goldman Sachs
New York
|
+$10.1M |
| 5 |
US Bancorp
Minneapolis,
Minnesota
|
+$8.25M |
Top Sellers
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$29.4M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$25.3M |
| 3 |
ACM
Alethea Capital Management
Mercer Island,
Washington
|
-$8.01M |
| 4 |
CM
Caption Management
Oklahoma City,
Oklahoma
|
-$4.98M |
| 5 |
D.E. Shaw & Co
New York
|
-$4.7M |
AXSM Hedge Fund Activity: Q2 2022 in Review
174 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q2 2022, worth a combined $827M — up 4.5% from $791M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new AXSM positions and 25 closed out — a net gain of 2 holders — while 67 added to existing stakes and 46 trimmed.
The largest buyer was PFM Health Sciences, opening a new position worth an estimated $43M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $29.4M sold.
- 174 institutional investors held Axsome Therapeutics (AXSM) as of Q2 2022, unchanged from Q1 2022.
- Funds reported $827M of Axsome Therapeutics stock for Q2 2022, up 4.5% quarter-over-quarter.
- 27 funds opened new Axsome Therapeutics positions in Q2 2022 and 25 closed out, a net change of +2 holders.
- The largest Axsome Therapeutics buyer in Q2 2022 was PFM Health Sciences, an estimated $43M added.
- The largest Axsome Therapeutics seller in Q2 2022 was Avidity Partners Management, an estimated $29.4M sold.
Based on aggregated 13F filings for Q2 2022.